Preliminary results of a phase I trial in patients with primary malignant gliomas using transfected mesenchymal stem cell with herpes simplex-thymidine kinase/ganciclovir complex

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 339

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

ITERMED01_426

تاریخ نمایه سازی: 7 مرداد 1398

چکیده مقاله:

The management of patients with glioblastoma remains challenging. Despite aggressive therapies, median survival for malignant gliomas is less than 15 months. Mesenchymal stem cells (MSCs) possess tumor-tropic properties and consequently have been used to deliver therapeutic agents for cancer treatment.In this study, six patients with newly diagnosed malignant glioma received autologous bone marrow MSC transfected by Herpes Simplex-Thymidine Kinase (HSV-tk) at vector particles through tumor bed injection 2 weeks after surgery and after confirmation of the pathology.They received ganciclovir as prodrug 14 days after tumor resection. All patients were treated by chemo radiation through or after completion of medication associated gene therapy. They have been following up every six months after intervention with history taking, filling questionnaire, physical examination and imaging. The first case enrolled in the study 15 months ago. The average time of follow up for patients are 12 months. One patient unfortunately passed away due to deep vein thrombosis and consequent pulmonary emboli that was unrelated to intervention. The rest of patients are living without any evidence of radiological or clinical recurrence. local or systemic toxicity or increased brain edema did not occur in this study.These data show that the MSC/HSV-tk/GC complex at the dose used in this study is safe. Long- term follow up and comparing with control group are needed to assess the efficacy of this combination for glioblastoma multiform treatment

نویسندگان

Ali-Reza Zali

Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Exellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Saeed Oraee-Yazdani

Stem Cell Technology Research Center, Tehran, Iran

Masoud Soleimani

Department of Hematology, Tarbiat Modares University, Tehran, Iran

Ehsan Arefian

Molecular Virology Lab, Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran